Clarametyx Continues Breakthrough Therapies with CincyTech Investment

CincyTech has announced its investment in Clarametyx Biosciences, a Columbus-based biotechnology company recognized for pioneering immune-enabling solutions targeting bacterial biofilm-related chronic respiratory diseases. This investment is intended to advance the development of Clarametyx's flagship drug candidate, CMTX-101, a novel monoclonal antibody designed to combat persistent infections predominantly affecting cystic fibrosis patients. Clarametyx, established in 2020 as a spinout from Nationwide Children’s Hospital, has seen rapid progress with its anti-biofilm technology, having completed successful Phase 1 clinical trials and preparing for a critical Phase 2a trial. CMTX-101 aims to disrupt biofilms by targeting the DNABII protein, which is crucial for biofilm stability, potentially revolutionizing treatments for chronic lung diseases where biofilm-driven infections are major mortality factors. Emma Off, CEO of CincyTech, emphasizes the transformational potential of Clarametyx's platform in managing chronic infections. The Phase 2a trial's interim analysis is viewed as pivotal for Clarametyx's value growth. In addition to funding CMTX-101, the Series A extension funding will support the advancement of the CMTX-301 vaccine program, targeting DNABII proteins. This strategic funding, characterized as more than just financial support but a collaborative partnership, reflects CincyTech's commitment to scaling early-stage biotech enterprises.